Previous page Manuela INGALLINESI Postdoctoral Researcher Team "Biotechnology et biotherapy" (Bio-Modeling in Neurodegenerative Diseases)


Project: The role of the G-protein coupled receptor 88 (Gpr88) in Parkinson’s disease Her research focus on characterizing the role of Gpr88 in the motor dysfunctions typical of Parkinson’s disease as well as induced by the lead pharmacological treatment, the L-DOPA (L-Dopa- induced dyskinesia). Using the gene transfer strategy to knock-down locally Gpr88 in the medium spiny neurons of the striatum, Manuela and her collaborators investigate the behavioral and the molecular components modulate by Gpr88 in rodent models of the disease.


  • Ingallinesi M, Le Bouil L, Faucon Biguet N, Do Thi A, Mannoury la Cour C, Millan MJ, Ravassard P, Mallet J, Meloni R. (2015). Local inactivation of Gpr88 in the Nucleus Accumbens attenuates behavioral deficits elicited by the neonatal administration of phencyclidine in rats. Molecular Psychiatry, 20 (8): 951-8.
  • Watson DJ, Loiseau F, Ingallinesi M, Millan MJ, Marsden CA, Fone KC. (2012). Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex. Neuropsychopharmacology, 37 (3): 770-86.
  • Ingallinesi M, Rouibi K, Le Moine C, Papaleo F, Contarino A. (2012) CRF2 receptor-deficiency eliminates opiate withdrawal distress without impairing stress coping. Molecular Psychiatry, 17 (12): 1283-94.
  • Papaleo F, Ghozland S, Ingallinesi M, Roberts AJ, Koob GF, Contarino A. (2008). Disruption of the CRF(2) receptor pathway decreases the somatic expression of opiate withdrawal. Neuropsychopharmacology, 33 (12): 2878-87.